Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
hospital acquired and ventilator associated bacterial pneumonia habpvabp market size

SALE

Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) - Market Insight, Epidemiology and Market Forecast - 2028

Published Date : 2019

Pages : 285

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

hospital acquired and ventilator associated bacterial pneumonia habpvabp market size

DelveInsight's 'Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP)- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as, the market trends of HABP/VABP in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of HABP/VABP from 2017 to 2028 segmented by the seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2017-2028

Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) - Disease Understanding and Treatment Algorithm

The DelveInsight's HABP/VABP market report gives a thorough understanding of the HABP/VABP by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for HABP/VABP in the US, Europe, and Japan.

Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) - Epidemiology

The HABP/VABP epidemiology division provide insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight's report also provides the diagnosed patient pool and their trends along with undertaken assumptions.

The disease epidemiology covered in the report provides historical, as well as, forecasted epidemiology [segmented by Total Incident Population, Total Diagnosed Incident Population, Diagnosed Incidence of HABP by Causative Pathogens, and Diagnosed Incidence of VABP by Causative Pathogens] scenario of HABP/VABP in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2028.

DelveInsight's estimations suggest that the total Incident Population of HABP in the 7MM was assessed to be 1,342,552 in 2017, whereas total Incident Population of VABP, as assessed by DelveInsight's analysts was evaluated to be 362,351 in 2017.

The estimates showed a higher incidence of HABP and VABP in the United States. Among the European 5 countries, Germany had the highest incident population of HABP/VABP, followed by the United Kingdom and France. On the other hand, Spain had the lowest incident population. Japan had 219,673 incident cases for HABP/VABP in 2017.

As per DelveInsight's analysis, 90-95% of the incident cases of HABP and VABP are confirmed with specific bacterial species. Diagnosed Incident cases of HABP and VABP in the 7MM were observed to be 1,239,174 and 337,825, respectively, in 2017. Estimations as per our analysts, the Gram-negative bacteria are implicated in 65-70% of the cases of HABP and VABP, whereas Gram-positive bacteria account for 30-35% of the cases of HABP and VABP.

Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) - Drug Chapters

This segment of the HABP/VABP report encloses the detailed analysis of marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

AVYCAZ (ceftazidime and avibactam) is a fixed-dose combination antibacterial indicated for the treatment of HABP/VABP. It is an antibacterial combination product consisting of the semi-synthetic cephalosporin ceftazidime pentahydrate and the beta-lactamase inhibitor avibactam sodium for intravenous administration. Currently, Ceftazidime and avibactam are being jointly developed by Allergan and Pfizer. Allergan holds the rights to commercialize ceftazidime and avibactam in North America under the brand name AVYCAZ.

Another drug approved by the US FDA is Vibativ (telavancin), which is an injectable antibiotic used for the treatment of certain serious bacterial infections including HABP/VABP. Telavancin is a lipoglycopeptide antibiotic exerting a concentration-dependent bactericidal activity. It is a semisynthetic derivative of vancomycin with a hydrophobic side chain attached to the vancosamine sugar. The activity of telavancin is due to the novel combined action on the cell wall synthesis and disruption of bacterial cell membrane barrier function.

Zevtera (Ceftobiprole) is a new generation broad-spectrum intravenous cephalosporin antibiotic with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. The drug is approved for sale in 13 European countries (European trade name Zevtera or Mabelio, depending on the country) and several non-European countries for the treatment of HABP, excluding VABP. Basilea Pharmaceutica is currently marketing the drug in Germany, Italy, the UK, France, Austria, and Switzerland and have already established license and distribution agreements for ceftobiprole with several partners in European regions. The anticipated patent expiration for Zevtera is in 2019, however, the company holds an option to extend for further five years.

Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) - Market Outlook

The HABP/VABP market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The current therapeutic landscape of HABP/VABP in the United States is driven by two of the approved therapies, namely Avycaz and Vibativ, along with off-label therapies. In EU-5-countries, for HABP/VABP, the market is mainly attributed to three of the approved therapies, namely Avycaz, Vibativ, and Zevtera, along with off-label therapies. In contrast to the US and EU-5 countries, the current therapeutic landscape of HABP/VABP in Japan is driven by off-label therapies. There is no approved drug, at present, in Japan, for the treatment of HABP/VABP.

Combination therapies remain the mainstay in the treatment of HABP/VABP, irrespective of the causative agents (gram positive or negative). Among the class of antibiotics prescribed to patients in the category of gram-positive bacteria, Glycopeptides occupy the largest market share, followed by Oxazolidinones. Furthermore, in the class of antibiotics prescribed to those who suffer from HABP/VABP due to gram positive bacteria, Cephalosporins contribute highest to the market size, while Polymyxins remain the least prescribed option in the 7MM countries.

Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP) - Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The future of HABP management is likely to be dominated by the reality of increasing antimicrobial resistance. Resistance spreads for a number of reasons, with overuse of antibiotics and sharing of DNA between organisms being among the important drivers. Many new therapies are in the pipeline for the treatment of HABP/VABP. Most of these may halt or slow the progression of the disease but there remains a dearth of information to prove whether these can completely reverse the disease. Companies across the globe have shifted their focus to the development of drugs to cure the disease caused by different causative agents. To name a few of these: Basilea Pharmaceutica, Merck, Cubist Pharmaceuticals, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Arsanis, Motif Bio, and others.

While a few of the aforementioned companies have either entered or are on a verge of completing Phase III stage of clinical development, yet others have recently initiated the evaluation of their products in the Phase II clinical development stage. Companies with their products, which are in the Phase III stage of development, and are expected to rule the therapeutic market of this disease include: Zevtera (Basilea), MK-1986 (Merck), MK-7625A (Merck), S-649266 (Shionogi), PF06947387 (Pfizer), AR-301 (Aridis Pharmaceuticals), and Murepavadin (Polyphor).

Out of Phase III emerging therapies, Merck's MK-7625A (Zerbaxa; ceftolozane/tazobactam), targeting Gram-Negative Bacteria, is expected to win the race in terms of its launch before other drug candidates, in the 7MM countries. This will be followed by the contribution of drug AR-301 (Salvecin; Aridis Pharmaceuticals).

On the other hand, among the Phase II drugs in the pipeline, AR-105 (Aerucin; Aridis Pharmaceuticals) is expected to take the lead, followed by revenue generated by Iclaprim (Motif Bio).

HABP/VABP Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

HABP/VABP Report Key Strengths

• 10 Years Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Key Cross Competition

• Market Size by Therapies

• Drugs Uptake

HABP/VABP Report Assessment

• Pipeline Product Profiles

• Key Products and Key Players

• Market Drivers and Barriers

Key Benefits

• This report will help to develop Business Strategies by understanding the trends shaping and driving the HABP/VABP market.

• Organize sales and marketing efforts by identifying the best opportunities for HABP/VABP market.

• To understand the future market competition in the HABP/VABP market.

1. Key Insights

2. Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP): Market Overview at a Glance

2.1. Total Market Share (%) Distribution of HABP/VABP in 2017

2.2. Total Market Share (%) Distribution of HABP/VABP in 2028

3. Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP): Disease Background and Overview

3.1. Introduction

3.2. Microbiology of HABP

3.3. Causes and Risk Factors

3.3.1. Early-Onset and Late-Onset Pneumonia: Influence of Duration of Hospitalization on Etiologic Agent

3.3.2. Influence of Prior Antibiotics on the Causative Pathogen

3.3.3. Mechanical Ventilation as a Risk Factor for HAP

3.3.4. Role of Oropharyngeal, Tracheal, and Gastric Colonization

3.3.5. Other Potential Causes of HAP

3.3.6. Acute Respiratory Distress Syndrome (ARDS)

3.3.7. Role of Prophylactic Antibiotics

3.4. Pathophysiology

3.5. Diagnosis

3.5.1. Diagnosis of Ventilator-associated bacterial pneumonia

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Total Incident Population of HABP in the 7MM

4.3. Total Incident Population of VABP in the 7MM

4.4. Total Diagnosed Incident Population of HABP/VABP in the 7MM

4.5. Diagnosed Incidence of HABP/VABP by Causative Pathogens in the 7MM

5. United States Epidemiology

5.1. Assumptions and Rationale

5.2. Total Incident Population of HABP/VABP in the United States

5.3. Total Diagnosed Incident Population of HABP/VABP in the United States

5.4. Diagnosed Incidence of HABP by Causative Pathogens in the United States

5.5. Diagnosed Incidence of VABP by Causative Pathogens in the United States

6. EU5 Epidemiology

6.1. Assumptions and Rationale

6.2. Germany Epidemiology

6.2.1. Assumptions and Rationale

6.2.2. Total Incident Population of HABP/VABP in Germany

6.2.3. Total Diagnosed Incident Population of HABP/VABP in Germany

6.2.4. Diagnosed Incidence of HABP by Causative Pathogens in Germany

6.2.5. Diagnosed Incidence of VABP by Causative Pathogens in Germany

6.3. France Epidemiology

6.3.1. Assumptions and rationale

6.3.2. Total Incident Population of HABP/VABP in France

6.3.3. Total Diagnosed Incident Population of HABP/VABP in France

6.3.4. Diagnosed Incidence of HABP by Causative Pathogens in France

6.3.5. Diagnosed Incidence of VABP by Causative Pathogens in France

6.4. Italy Epidemiology

6.4.1. Assumptions and Rationale

6.4.2. Total Incident Population of HABP/VABP in Italy

6.4.3. Total Diagnosed Incident Population of HABP/VABP in Italy

6.4.4. Diagnosed Incidence of HABP by Causative Pathogens in Italy

6.4.5. Diagnosed Incidence of VABP by Causative Pathogens in Italy

6.5. Spain Epidemiology

6.5.1. Assumptions and Rationale

6.5.2. Total Incident Population of HABP/VABP in Spain

6.5.3. Total Diagnosed Incident Population of HABP/VABP in Spain

6.5.4. Diagnosed Incidence of HABP by Causative Pathogens in Spain

6.5.5. Diagnosed Incidence of VABP by Causative Pathogens in Spain

6.6. United Kingdom Epidemiology

6.6.1. Assumptions and Rationale

6.6.2. Total Incident Population of HABP/VABP in the United Kingdom

6.6.3. Total Diagnosed Incident Population of HABP/VABP in the United Kingdom

6.6.4. Diagnosed Incidence of HABP by Causative Pathogens in the United Kingdom

6.6.5. Diagnosed Incidence of VABP by Causative Pathogens in the United Kingdom

7. Japan Epidemiology

7.1. Assumptions and Rationale

7.2. Total Incident Population of HABP/VABP in Japan

7.3. Total Diagnosed Incident Population of HABP/VABP in Japan

7.4. Diagnosed Incidence of HABP by Causative Pathogens in Japan

7.5. Diagnosed Incidence of VABP by Causative Pathogens in Japan

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Prevention

8.2. Management of HABP

8.3. Empiric Treatment of HAP

8.4. Treatment of Pseudomonal HAP

8.5. Combination of Aminoglycoside and b-Lactam Antibiotics

8.6. Carbapenems

8.7. Cephalosporins

8.8. Combination Therapy with ?-Lactam and Fluoroquinolones

8.9. Piperacillin/Tazobactam

9. Proposed Guidelines for the Diagnosis and Treatment of HABP and VABP

9.1. New guidelines for hospital-acquired pneumonia/ ventilator-associated pneumonia: the USA vs. Europe

9.1.1. Prevention

9.1.2. Diagnosis

9.1.3. Microbiologic Methods to Diagnose Ventilator-Associated Pneumonia and Hospital-Acquired Pneumonia

9.1.4. Treatment

9.2. Hospital-acquired pneumonia guidelines in Europe: a review of their status and future development

9.2.1. Existing European HAP guidelines

9.2.2. HAP diagnosis (eight guidelines)

9.2.3. HAP treatment (eight guidelines)

9.2.4. HAP prevention (eight guidelines)

9.2.5. Model guidelines

9.2.6. Approaches to guideline development

9.2.7. Principles for HAP guidelines

9.2.8. Pan-European HAP guidelines

9.2.9. Guideline implementation

9.3. Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy

9.4. A consensus paper of the German Society of Pneumology (DGP) and the Paul Ehrlich Society for Chemotherapy (PEG) in collaboration with experts from the German Society for Anaesthesiology and Intensive Care (DGAI) Nosocomial Pneumonia: Prevention, Diagnosis, Treatment

9.4.1. Prevention

9.4.2. Diagnostics

9.4.3. Antibiotics

9.4.4. Therapy

9.5. A brief summary of French guidelines for the prevention, diagnosis, and treatment of hospital-acquired pneumonia in ICU

9.6. Recommendations for the Treatment of Severe Nosocomial Pneumonia (Spain)

9.6.1. Treatment Protocols for Nosocomial Pneumonia Drawn Up by Scientific Associations. Definition of Risk Categories

9.6.2. Indications for ICU Admission of Patients with Nosocomial Pneumonia

9.6.3. Treatment of Severe Nosocomial VAP

9.6.4. Special Situations

10. Unmet Needs

11. Marketed Products

11.1. Avycaz/Zavicefta (ceftazidime and avibactam): Allergan; Pfizer

11.1.1. Drug Description

11.1.2. Mechanism of Action

11.1.3. Regulatory Milestones

11.1.4. Product Development Activities

11.1.5. Advantages & Disadvantages

11.1.6. Safety and Efficacy

11.1.7. Product Profile

11.2. Vibativ (Telavancin): Theravance Biopharma/Cumberland Pharmaceuticals

11.2.1. Drug Description

11.2.2. Mechanism of Action

11.2.3. Regulatory Milestones

11.2.4. Product Development Activities

11.2.5. Safety and Efficacy

11.2.6. Product Profile

11.3. Zevtera/Mabelio: Basilea Pharmaceuticals

11.3.1. Drug Description

11.3.2. Mechanism of action

11.3.3. Regulatory Milestones

11.3.4. Product Development Activities

11.3.5. Advantages & Disadvantages

11.3.6. Safety and Efficacy

11.3.7. Product Profile

12. Emerging Therapies

12.1. Key Cross Competition

12.2. MK-1986 (SIVEXTRO): Merck

12.2.1. Drug Description

12.2.2. Other Development Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

12.3. MK-7625A (ZERBAXA): Merck

12.3.1. Drug Description

12.3.2. Other Development Activities

12.3.3. Clinical Development

12.3.4. Safety and Efficacy

12.3.5. Product Profile

12.4. Cefiderocol (S-649266): Shionogi

12.4.1. Drug Description

12.4.2. Other Development Activities

12.4.3. Clinical Development

12.4.4. Product Profile

12.5. PF06947387 (aztreonam-avibactam): Pfizer

12.5.1. Drug Description

12.5.2. Other Development Activities

12.5.3. Clinical Development

12.5.4. Product Profile

12.6. AR-301 mAb: Aridis Pharmaceuticals

12.6.1. Drug Description

12.6.2. Other Development Activities

12.6.3. Clinical Development

12.6.4. Safety and Efficacy

12.6.5. Product Profile

12.7. Murepavadin (POL7080): Polyphor

12.7.1. Drug Description

12.7.2. Other Development Activities

12.7.3. Clinical Development

12.7.4. Safety and Efficacy

12.7.5. Product Profile

12.8. AR-105 mAb: Aridis Pharmaceuticals

12.8.1. Drug Description

12.8.2. Other Development Activities

12.8.3. Clinical Development

12.8.4. Safety and Efficacy

12.8.5. Product Profile

12.9. AR-101 mAb: Aridis Pharmaceuticals

12.9.1. Drug Description

12.9.2. Other Development Activities

12.9.3. Clinical Development

12.9.4. Safety and Efficacy

12.9.5. Product Profile

12.10. Iclaprim: Motif Bio

12.10.1. Product Description

12.10.2. Other Developmental Activities

12.10.3. Clinical Development

12.10.4. Safety and Efficacy

12.10.5. Product Profile

12.11. ASN100: Arsanis

12.11.1. Drug Description

12.11.2. Other Development Activities

12.11.3. Clinical Development

12.11.4. Safety and Efficacy

12.11.5. Product Profile

13. HABP/VABP: 7MM Market Analysis

13.1. Key Findings

13.2. Market Size of HABP/VABP in 7MM

13.3. Market Size of HABP/VABP by Therapies in the 7MM

13.4. Market Forecast Assumptions

14. United States: Market Outlook

14.1. United States Market Size

14.1.1. Total Market size of HABP/VABP

14.1.2. Market Size of HABP/VABP by Therapies in the US

15. EU-5 countries: Market Outlook

15.1. Germany Market Size

15.1.1. Total Market size of HABP/VABP

15.1.2. Market Size of HABP/VABP by therapies in Germany

15.2. France Market Size

15.2.1. Total Market size of HABP/VABP

15.2.2. Market Size of HABP/VABP by therapies in France

15.3. Italy Market Size

15.3.1. Total Market size of HABP/VABP

15.3.2. Market Size of HABP/VABP by therapies in Italy

15.4. Spain Market Size

15.4.1. Total Market size of HABP/VABP

15.4.2. Market Size of HABP/VABP by therapies in Spain

15.5. United Kingdom Market Size

15.5.1. Total Market size of HABP/VABP

15.5.2. Market Size of HABP/VABP by therapies in the UK

16. Japan Market Outlook

16.1. Japan Market Size

16.1.1. Total Market size of HABP/VABP

16.1.2. Market Size of HABP/VABP by therapies in Japan

17. Market Drivers

18. Market Barriers

19. Appendix

19.1. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Tables:

Table 1: Risk factors of ventilator-associated pneumonia

Table 2: Total Incident Population of HABP in the 7MM (2017-2028)

Table 3: Total Incident Population of VABP in the 7MM (2017-2028)

Table 4: Total Diagnosed Incident Population of HABP/VABP in the 7MM (2017-2028)

Table 5: Diagnosed Incidence of HABP/VABP by Causative Pathogens in the 7MM (2017-2028)

Table 6: Total Incident Population of HABP/VABP in the US (2017-2028)

Table 7: Total Diagnosed Incident Population of HABP/VABP in the US (2017-2028)

Table 8: Diagnosed Incidence of HABP by Causative Pathogens in the US (2017-2028)

Table 9: Diagnosed Incidence of VABP by Causative Pathogens in the US (2017-2028)

Table 10: Total Incident Population of HABP/VABP in Germany (2017-2028)

Table 11: Total Diagnosed Incident Population of HABP/VABP in Germany (2017-2028)

Table 12: Diagnosed Incidence of HABP by Causative Pathogens in Germany (2017-2028)

Table 13: Diagnosed Incidence of VABP by Causative Pathogens in Germany (2017-2028)

Table 14: Total Incident Population of HABP/VABP in France 2017-2028)

Table 15: Total Diagnosed Incident Population of HABP/VABP in France (2017-2028)

Table 16: Diagnosed Incidence of HABP by Causative Pathogens in France (2017-2028)

Table 17: Diagnosed Incidence of VABP by Causative Pathogens in France (2017-2028)

Table 18: Total Incident Population of HABP/VABP in Italy 2017-2028)

Table 19: Total Diagnosed Incident Population of HABP/VABP in Italy (2017-2028)

Table 20: Diagnosed Incidence of HABP by Causative Pathogens in Italy (2017-2028)

Table 21: Diagnosed Incidence of VABP by Causative Pathogens in Italy (2017-2028)

Table 22: Total Incident Population of HABP/VABP in Spain 2017-2028)

Table 23: Total Diagnosed Incident Population of HABP/VABP in Spain (2017-2028)

Table 24: Diagnosed Incidence of HABP by Causative Pathogens in Spain (2017-2028)

Table 25: Diagnosed Incidence of VABP by Causative Pathogens in Spain (2017-2028)

Table 26: Total Incident Population of HABP/VABP in the United Kingdom 2017-2028)

Table 27: Total Diagnosed Incident Population of HABP/VABP in the United Kingdom (2017-2028)

Table 28: Diagnosed Incidence of HABP by Causative Pathogens in the United Kingdom (2017-2028)

Table 29: Diagnosed Incidence of VABP by Causative Pathogens in the United Kingdom (2017-2028)

Table 30: Total Incident Population of HABP/VABP in Japan 2017-2028)

Table 31: Total Diagnosed Incident Population of HABP/VABP in Japan (2017-2028)

Table 32: Diagnosed Incidence of HABP by Causative Pathogens in Japan (2017-2028)

Table 33: Diagnosed Incidence of VABP by Causative Pathogens in Japan (2017-2028)

Table 34: Treatment rationale for risk factors in European and American guidelines.

Table 35: Main differences between the European and American guidelines recommendations

Table 36: Principles for the production of pan-European HAP guidelines

Table 37: Guidelines for the management of hospital-acquired pneumonia in the UK

Table 38: MK-1986,Clinical Trial Description, 2019

Table 39: MK-7655A, Clinical Trial Description, 2019

Table 40: S-649266,Clinical Trial Description, 2019

Table 41: PF06947387,Clinical Trial Description, 2019

Table 42: AR-301,Clinical Trial Description, 2019

Table 43: Murepavadin, Clinical Trial Description, 2019

Table 44: AR-105,Clinical Trial Description, 2019

Table 45: AR-101,Clinical Trial Description, 2019

Table 46: Iclaprim, Clinical Trial Description

Table 47: ASN100,Clinical Trial Description, 2019

Table 48: Market Size of HABP/VABP in 7MM in USD Million (2017-2028)

Table 49: Market Size of HABP/VABP by therapies in the 7MM, in USD Million (2017-2028)

Table 50: Expected Launch Date of Emerging Therapies in the 7MM

Table 51: The US Market Size of HABP/VABP in USD Million (2017-2028)

Table 52: Market Size of HABP/VABP by therapies in the US, in USD Million (2017-2028)

Table 53: Germany Market Size of HABP/VABP in USD Million (2017-2028)

Table 54: Market Size of HABP/VABP by therapies in Germany, in USD Million (2017-2028)

Table 55: France Market Size of HABP/VABP in USD Million (2017-2028)

Table 56: Market Size of HABP/VABP by therapies in France, in USD Million (2017-2028)

Table 57: Italy Market Size of HABP/VABP in USD Million (2017-2028)

Table 58: Market Size of HABP/VABP by therapies in Italy, in USD Million (2017-2028)

Table 59: Spain Market Size of HABP/VABP in USD Million (2017-2028)

Table 60: Market Size of HABP/VABP by therapies in Spain, in USD Million (2017-2028)

Table 61: The UK Market Size of HABP/VABP in USD Million (2017-2028)

Table 62: Market Size of HABP/VABP by therapies in the United Kingdom, in USD Million (2017-2028)

Table 63: Japan Market Size of HABP/VABP in USD Million (2017-2028)

Table 64:Market Size of HABP/VABP by therapies in Japan, in USD Million (2017-2028)

List of Figures:

Figure 1: Risk Factors for the Development of HAP

Figure 2: The most common sources and pathogenic organisms associated with hospital-acquired and ventilator-associated pneumonia

Figure 3: Algorithm for diagnosis and treatment of VABP

Figure 4: Total Incident Population of HABP in the 7MM (2017-2028)

Figure 5: Total Incident Population of VABP in the 7MM (2017-2028)

Figure 6: Total Diagnosed Incident Population of HABP/VABP in the 7MM (2017-2028)

Figure 7: Diagnosed Incidence of HABP/VABP by Causative Pathogens in the 7MM (2017-2028)

Figure 8: Total Incident Population of HABP/VABP in the US (2017-2028)

Figure 9: Total Diagnosed Incident Population of HABP/VABP in the US (2017-2028)

Figure 10: Diagnosed Incidence of HABP by Causative Pathogens in the US (2017-2028)

Figure 11: Diagnosed Incidence of VABP by Causative Pathogens in the US (2017-2028)

Figure 12: Total Incident Population of HABP/VABP in Germany (2017-2028)

Figure 13: Total Diagnosed Incident Population of HABP/VABP in Germany (2017-2028)

Figure 14: Diagnosed Incidence of HABP by Causative Pathogens in Germany (2017-2028)

Figure 15: Diagnosed Incidence of VABP by Causative Pathogens in Germany (2017-2028)

Figure 16: Total Incident Population of HABP/VABP in France (2017-2028)

Figure 17: Total Diagnosed Incident Population of HABP/VABP in France (2017-2028)

Figure 18: Diagnosed Incidence of HABP by Causative Pathogens in France (2017-2028)

Figure 19: Diagnosed Incidence of VABP by Causative Pathogens in France (2017-2028)

Figure 20: Total Incident Population of HABP/VABP in Italy (2017-2028)

Figure 21: Total Diagnosed Incident Population of HABP/VABP in Italy (2017-2028)

Figure 22: Diagnosed Incidence of HABP by Causative Pathogens in Italy (2017-2028)

Figure 23: Diagnosed Incidence of VABP by Causative Pathogens in Italy (2017-2028)

Figure 24: Total Incident Population of HABP/VABP in Spain (2017-2028)

Figure 25: Total Diagnosed Incident Population of HABP/VABP in Spain (2017-2028)

Figure 26: Diagnosed Incidence of HABP by Causative Pathogens in Spain (2017-2028)

Figure 27: Diagnosed Incidence of VABP by Causative Pathogens in Spain (2017-2028)

Figure 28: Total Incident Population of HABP/VABP in the United Kingdom (2017-2028)

Figure 29: Total Diagnosed Incident Population of HABP/VABP in the United Kingdom (2017-2028)

Figure 30: Diagnosed Incidence of HABP by Causative Pathogens in the United Kingdom (2017-2028)

Figure 31: Diagnosed Incidence of VABP by Causative Pathogens in the United Kingdom (2017-2028)

Figure 32: Total Incident Population of HABP/VABP in Japan (2017-2028)

Figure 33: Total Diagnosed Incident Population of HABP/VABP in Japan (2017-2028)

Figure 34: Diagnosed Incidence of HABP by Causative Pathogens in Japan (2017-2028)

Figure 35: Diagnosed Incidence of VABP by Causative Pathogens in Japan (2017-2028)

Figure 36: Algorithm for an empirical antibiotic approach for HAP, VAP, and HCAP.

Figure 37: Algorithm for the diagnosis of nosocomial pneumonia

Figure 38: Nosocomial Pneumonia With a Poor Response to Antibiotic Treatment (>72 h)

Figure 39: Algorithm for the treatment of severe nosocomial pneumonia.

Figure 40: Unmet Needs of HABP & VABP

Figure 41: Market Size of HABP/VABP in the 7MM in USD Million (2017-2028)

Figure 42: Market Size of HABP/VABP by therapies in the 7MM, in USD Million (2017-2028)

Figure 43: Market Size of HABP/VABP in the US, USD Millions (2017-2028)

Figure 44: Market Size of HABP/VABP by therapies in the United States, in USD Million (2017-2028)

Figure 45: Market Size of HABP/VABP in Germany, USD Millions (2017-2028)

Figure 46: Market Size of HABP/VABP by therapies in Germany, in USD Million (2017-2028)

Figure 47: Market Size of HABP/VABP in France, USD Millions (2017-2028)

Figure 48: Market Size of HABP/VABP by therapies in France, in USD Million (2017-2028)

Figure 49: Market Size of HABP/VABP in Italy, USD Millions (2017-2028)

Figure 50: Market Size of HABP/VABP by therapies in Italy in USD Million (2017-2028)

Figure 51: Market Size of HABP/VABP in Spain, USD Millions (2017-2028)

Figure 52: Market Size of HABP/VABP by therapies in Spain in USD Million (2017-2028)

Figure 53: Market Size of HABP/VABP in the UK, USD Millions (2017-2028)

Figure 54: Market Size of HABP/VABP by therapies in the UK in USD Million (2017-2028)

Figure 55: Market Size of HABP/VABP in Japan, USD Millions (2017-2028)

Figure 56: Market Size of HABP/VABP by therapies in Japan in USD Million (2017-2028)

Figure 57: Market Drivers

Figure 58:Market Barriers

Tags:

License Type

Offer